The days of one-size-fits-all therapies are being replaced by individualized treatments and disease interventions. In cancer, standard therapies are ineffective in an average of three-quarters of patients, one of the highest therapy failure rates for all diseases.1 Precision oncology describes a diverse set of strategies in cancer medicine tailored to the unique biology of a patient’s disease. Strategies range from the use of targeted therapies to the use of data from next-generation sequencing to select treatments independent of cancer-type. Precision oncology holds the promise of improved efficiency, better care and the reduction of ineffective treatments and costs. However, important work remains to prepare the oncological ecosystem to leverage the full potential of personalized medicine in oncology. To test the status quo, identify barriers to adoption and help unlock precision oncology’s full value, we surveyed 130 oncologists from the US and Europe as part of the Accenture Study on Precision Oncology in Practice.
Widespread use of precision oncology hinges on adoption
Oncologists say they need:
Steps to drive adoption
It’s clear that precision oncology’s importance will grow significantly in the next few years, but to achieve the desired goals, a clear course must be plotted. Our research shows the oncology ecosystem requires four essential steps to capture the full potential of precision oncology:
1 Spear, B. B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201–204 (2001)